Literature DB >> 9443850

Nicotine metabolism in liver microsomes from rats with acute hepatitis or cirrhosis.

M Nakajima1, K Iwata, T Yamamoto, Y Funae, T Yoshida, Y Kuroiwa.   

Abstract

Nicotine exerts a number of physiological effects. Nicotine is absorbed through the lungs with smoking and is rapidly metabolized in humans. Although it is mainly metabolized in the liver, the effects of liver injuries on nicotine metabolism are not clear. The purpose of this study was to clarify the effects of liver injuries on nicotine metabolism. Rats were treated with D-galactosamine (GalN) or thioacetamide (TA), to induce acute hepatitis or liver cirrhosis, respectively. Serum transaminase levels were significantly elevated in model rats with both types of liver injury. Cytochrome P450 (CYP) and cytochrome b5 contents in liver microsomes were decreased significantly in TA-treated cirrhotic rats but not in GalN-treated hepatitic rats. The major metabolic pathways of nicotine, i.e. cotinine formation catalyzed by CYP and nicotine-1'-N-oxide formation catalyzed by flavin-containing monooxygenase, were investigated in these rat liver microsomes. Formation of cotinine and nicotine-1'-N-oxide from nicotine was not changed in GalN-treated hepatitic rats, in comparison with the controls, but was significantly decreased in TA-treated cirrhotic rats. By immunoblotting, decreases in CYP1A2, CYP2B2, CYP2C, and CYP2E1 protein were recognized in liver microsomes from TA-treated cirrhotic rats. It was also shown that the maximal velocity values for nicotine-1'-N-oxide formation in TA-treated cirrhotic rats were significantly decreased, compared with the controls. These results suggested that the reduction of nicotine metabolism in cirrhosis was due to decreases in CYP and flavin-containing monooxygenase protein expression levels.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9443850

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data.

Authors:  Evelyn L Craig; Bin Zhao; Jason Z Cui; Maria Novalen; Sharon Miksys; Rachel F Tyndale
Journal:  Drug Metab Dispos       Date:  2014-06-30       Impact factor: 3.922

2.  Hepatic flavin-containing monooxygenase gene regulation in different mouse inflammation models.

Authors:  Jun Zhang; Madhusudana R Chaluvadi; Rob Reddy; Meike S Motika; Terrilyn A Richardson; John R Cashman; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2008-12-16       Impact factor: 3.922

3.  Chemopreventive effects of coumaperine from pepper on the initiation stage of chemical hepatocarcinogenesis in the rat.

Authors:  M Kitano; H Wanibuchi; H Kikuzaki; N Nakatani; S Imaoka; Y Funae; S Hayashi; S Fukushima
Journal:  Jpn J Cancer Res       Date:  2000-07

4.  Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers.

Authors:  Sally A El Awdan; Rehab F Abdel Rahman; Heba M Ibrahim; Rehab R Hegazy; Salma A El Marasy; Manal Badawi; Mahmoud S Arbid
Journal:  PLoS One       Date:  2019-05-08       Impact factor: 3.240

5.  Telmisartan Self-Nanoemulsifying Drug Delivery System, Compared With Standard Telmisartan, More Effectively Improves Hepatic Fibrosis in Rats.

Authors:  Hussam Murad; Osama Ahmed; Tawfik Ghabrah; Mamdooh Gari
Journal:  Dose Response       Date:  2020-12-17       Impact factor: 2.658

6.  Hepatoprotective Role of Ethanolic Extract of Vitex negundo in Thioacetamide-Induced Liver Fibrosis in Male Rats.

Authors:  Farkaad A Kadir; Normadiah M Kassim; Mahmood A Abdulla; Wageeh A Yehye
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-19       Impact factor: 2.629

Review 7.  Nicotine in Senescence and Atherosclerosis.

Authors:  Ann Marie Centner; Pradeep G Bhide; Gloria Salazar
Journal:  Cells       Date:  2020-04-22       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.